Corrected QT Interval Effects of Trastuzumab Emtansine (T-DM1) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer and the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression

Clinical trial NCT00943670 · COMPLETED

Trial details

NCT number: NCT00943670
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Breast Cancer

Start date: 2009-07-01
Primary completion: 2010-12-01
Enrollment: 51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.